Laura Paris
Brescia, Italy
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 30 publications
Clinical and Biological Implications of TP53 Abnormalities in Relapsed/Refractory Multiple Myeloma: The DEDALO Study.
Journal: Clinical lymphoma, myeloma & leukemia
Published: April 27, 2026
Salvage treatment patterns in multiple myeloma patients progressing after lenalidomide maintenance: A real-life study from European Myeloma Network (EMN) Italy.
Journal: British journal of haematology
Published: April 26, 2026
Successfully second line treatment with selinexor-bortezomib-dexamethasone of a patient affected by multiple myeloma, refractory to first line therapy with daratumab-lenalidomide-dexamethasone
Journal: Recenti progressi in medicina
Published: February 20, 2026
A nationwide Italian GIMEMA survey on tandem autologous stem cell transplantation for newly diagnosed multiple myeloma patients treated with daratumumab, bortezomib, thalidomide and dexamethasone.
Journal: Haematologica
Published: November 17, 2025
Subcutaneous daratumumab plus carfilzomib and dexamethasone (D-Kd) versus carfilzomib and dexamethasone (Kd) in patients with relapsed/refractory multiple myeloma who received previous daratumumab treatment: LYNX study.
Journal: Leukemia & lymphoma
Published: October 03, 2025
Pomalidomide, bortezomib and dexamethasone in multiple myeloma refractory to lenalidomide and anti- CD38 monoclonal antibodies: outcomes from a real-world experience.
Journal: Haematologica
Published: September 15, 2025
Addition of Daratumumab to First-Line Therapy of Newly Diagnosed Multiple Myeloma in Patients Eligible for Autologous Stem Cell Transplantation: A Single-Center Real-Life Experience.
Journal: Mediterranean journal of hematology and infectious diseases
Published: April 02, 2025
Prognostic Significance of +1q Alterations in Relapsed/Refractory Multiple Myeloma Treated With Daratumumab-, Elotuzumab-, and Carfilzomib-Based Triplet Regimens: A Multicenter Real-World Analysis of 635 Patients.
Journal: European journal of haematology
Published: January 31, 2025
Clinicians' Perspectives and Methodological Application of Fluorescence in situ Hybridization (FISH) to Define Cytogenetic Risk in Multiple Myeloma: An Italian, Real-World, Survey-Based Report From the European Myeloma Network (EMN) Italy.
Journal: Clinical lymphoma, myeloma & leukemia
Published: January 20, 2025
Feasibility and Outcome of First-Line Autotransplant-Based Treatment in Newly Diagnosed Multiple Myeloma Patients Aged > 65 Years: Monocentric Retrospective Real-World Analysis.
Journal: Mediterranean journal of hematology and infectious diseases
Published: June 27, 2024
Last Updated: 09/26/2026